Application of new biologic disease criteria for synucleinopathies to the systemic synuclein sampling study cohort

IF 6.7 1区医学 Q1 NEUROSCIENCES

NPJ Parkinson's Disease Pub Date : 2025-04-06 DOI:10.1038/s41531-025-00919-y

L. M. Chahine, M. C. Brumm, A. R. Nair, S. Mosovsky, N. K. Polinski, T. G. Beach, B. Mollenhauer, C. H. Adler

引用次数: 0

Abstract

We applied biologic criteria and NSD-ISS to Synuclein Sampling Study, a PD sample with range of durations since clinical diagnosis. 93% of evaluable participants met biologic criteria. The majority were NSD-ISS stage3 or less, including >40% of the advanced PD group. Interpretation of staging in medicated patients is challenging. Biologic criteria and clinico-biomarker staging are important steps forward, but quantitative biomarkers of disease progression, not influenced by medications, are critically needed.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Parkinson's Disease Medicine-Neurology (clinical)

CiteScore

9.80

自引率

5.70%

发文量

156

审稿时长

11 weeks

期刊介绍： npj Parkinson's Disease is a comprehensive open access journal that covers a wide range of research areas related to Parkinson's disease. It publishes original studies in basic science, translational research, and clinical investigations. The journal is dedicated to advancing our understanding of Parkinson's disease by exploring various aspects such as anatomy, etiology, genetics, cellular and molecular physiology, neurophysiology, epidemiology, and therapeutic development. By providing free and immediate access to the scientific and Parkinson's disease community, npj Parkinson's Disease promotes collaboration and knowledge sharing among researchers and healthcare professionals.